(HealthDay News) — An updated clinical guideline adds 2 new types of drugs to the list of treatment options for heart failure. The updated guideline was published online in the Journal of the American College of Cardiology, Circulation, and the Journal of Cardiac Failure.
The 2 new treatments in the updated guideline are an angiotensin receptor-neprilysin inhibitor (valsartan/sacubitril), sold as Entresto, and a sinoatrial node modulator (ivabradine), sold as Corlanor, according to the American College of Cardiology, the American Heart Association, and the Heart Failure Society of America.
Previously recommended drugs for these patients include angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta blockers, and diuretics.
“Treatment options for patients with heart failure have expanded considerably. There is more hope than ever before for patients with heart failure,” guideline update committee vice chair Mariell Jessup, MD, of the University of Pennsylvania School of Medicine in Philadelphia, said in a news release from the heart groups. “These guideline recommendations will serve as a tool to guide the choice of therapy and, in turn, improve outcomes.”
Several authors disclosed financial ties to the pharmaceutical industry.
- Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. J Am Coll Cardiol. doi:10.1016/j.jacc.2016.05.011.
- Antman EM, Bax J, Chazal RA, et al. Updated Clinical Practice Guidelines on Heart Failure: An International Alignment. J Am Coll Cardiol. doi:10.1016/j.jacc.2016.05.012.